Heinz Schwer

Chief Executive Officer & Co-Founder at Sloning Bio Technology GmbH

Heinz Schwer

Heinz Schwer

Chief Executive Officer & Co-Founder at Sloning Bio Technology GmbH

Overview
Career Highlights

ViraTherapeutics GmbH
LanthioPep BV
Lanthio Pharma BV

RelSci Relationships

73

Number of Boards

1

Birthday

06/1967

Age

51

Relationships
RelSci Relationships are individuals Heinz Schwer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Scientific Officer at Lanthio Pharma BV

Relationship likelihood: Strong

Chief Financial Officer at MorphoSys AG

Relationship likelihood: Strong

Chief Development Officer at MorphoSys AG

Relationship likelihood: Strong

Co-Founder at MorphoSys AG

Relationship likelihood: Strong

General Counsel at MorphoSys AG

Relationship likelihood: Strong

Head-Regulatory Affairs at MorphoSys AG

Relationship likelihood: Strong

Vice President & Head of Corporate Communications & Investor Relations at MorphoSys AG

Relationship likelihood: Strong

Head-Purchasing & Logistics at MorphoSys AG

Relationship likelihood: Strong

Head of Controlling, Corporate Finance & Corporate Development at MorphoSys AG

Relationship likelihood: Strong

Head-Information Technology at MorphoSys AG

Relationship likelihood: Strong

Paths to Heinz Schwer
Potential Connections via
Relationship Science
You
Heinz Schwer
Chief Executive Officer & Co-Founder at Sloning Bio Technology GmbH
Education

Henley Business School is a college of the University of Reading, offering bachelors and masters degrees.

University of Regensburg is a school in Regensburg.

Career History
Chief Executive Officer
2017 - Current

ViraTherapeutics GmbH develops biotechnology solutions. It develops potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Its proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. The company was founded by Dorothee Holm-von Laer in June 2012 and is headquartered in Innsbruck, Austria.

Chief Executive Officer & Co-Founder
2001 - Current

Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide.As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability.It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications.In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers.

Chief Executive Officer
Current

LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands.

Boards & Committees
Member, Scientific Advisory Board
2018 - Current

amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany.

Investments
Details Hidden

Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide.As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability.It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications.In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Heinz Schwer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Heinz Schwer's profile does not indicate a business or promotional relationship of any kind between RelSci and Heinz Schwer.